Key clinical point: Anifrolumab provides clinical benefit in moderate to severe SLE.
Major finding: BICLA response rates in TULIP-2 were 47.8% with anifrolumab versus 31.5% with placebo.
Study details: The phase 3 TULIP-1 and -2 trials involved a total of 819 patients.
Disclosures: The TULIP-1 and -2 trials were sponsored by AstraZeneca. Dr. Furie And Dr. Morand both reported grant/research support and consulting fees from AstraZeneca, as well as speaker’s bureau participation for AstraZeneca.